Adalimumab for sight-threatening uveitis in Behçet's disease

Eye (Lond). 2007 Jun;21(6):824-5. doi: 10.1038/sj.eye.6702352. Epub 2006 Apr 7.


Aims: To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.

Methods: Case note review. Main outcome measure was recurrence of uveitis.

Results: All patients remained free of recurrence with stable visual acuities.

Conclusions: Adalimumab appears to maintain disease remission in Behçet's disease.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Adult
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Behcet Syndrome / drug therapy*
  • Female
  • Humans
  • Male
  • Recurrence
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Uveitis / drug therapy*


  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • Adalimumab